Gα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia
JCI Insight · 2024
DOI: 10.1172/jci.insight.178993 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Birol Ay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit, Department of Medicine, and. Hauptthemen laut MEDLINE: Disease Models, Animal, Fibroblast Growth Factor-23, Fibroblast Growth Factors, GTP-Binding Protein alpha Subunits, Gq-G11. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Fibroblast growth factor 23 (FGF23) production has recently been shown to increase downstream of Gαq/11-PKC signaling in osteocytes. Inactivating mutations in the gene encoding Gα11 (GNA11) cause familial hypocalciuric hypercalcemia (FHH) due to impaired calcium-sensing receptor signaling. We explored the effect of Gα11 deficiency on FGF23 production in mice with heterozygous (Gna11+/-) or homozygous (Gna11-/-) ablation of Gna11. Both Gna11+/- and Gna11-/- mice demonstrated hypercalcemia and mildly raised parathyroid hormone levels, consistent with FHH. Strikingly, these mice also displayed increased serum levels of total and intact FGF23 and hypophosphatemia. Gna11-/- mice showed augmented Fgf23 mRNA levels in the liver and heart, but not in bone or bone marrow, and also showed evidence of systemic inflammation with elevated serum IL-1β levels. Furin gene expression was significantly increased in the Gna11-/- liver, suggesting enhanced FGF23 cleavage despite the observed rise in circulating intact FGF23 levels. Gna11-/- mice had normal renal function and reduced serum levels of glycerol-3-phosphate, excluding kidney injury as the primary cause of elevated intact FGF23 levels. Thus, Gα11 ablation caused systemic inflammation and excess serum FGF23 in mice, suggesting that patients with FHH - at least those with GNA11 mutations - may be at risk for these complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine Unit, Department of Medicine, and.
- Nephrology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Veterans Affairs, VA Boston Healthcare System, Boston, Massachusetts, USA.
- Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.
- Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Massachusetts, USA.
Förderung
- NIDDK NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
Zitieren
APA
Ay, B., Cyr, S. M., Klovdahl, K., Zhou, W., Tognoni, C. M., Iwasaki, Y., Rhee, E. P., Dedeoglu, A., Simic, P., & Bastepe, M. (2024). Gα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia. JCI Insight. https://doi.org/10.1172/jci.insight.178993
Vancouver
Ay B, Cyr SM, Klovdahl K, Zhou W, Tognoni CM, Iwasaki Y, et al. Gα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia. JCI Insight. 2024. doi:10.1172/jci.insight.178993
BibTeX
@article{Ay2024,
author = {Ay, Birol and Cyr, Sajin Marcus and Klovdahl, Kaitlin and Zhou, Wen and Tognoni, Christina M and Iwasaki, Yorihiro and Rhee, Eugene P and Dedeoglu, Alpaslan and Simic, Petra and Bastepe, Murat},
title = {Gα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia},
journal = {JCI Insight},
year = {2024},
doi = {10.1172/jci.insight.178993}
}
EUVIMED